Biogen Inc [BIIB] stock prices are up 1.69% to $191.56 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BIIB shares have gain 4.48% over the last week, with a monthly amount drifted -2.08%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Needham reaffirmed its Buy rating on February 14, 2024, and dropped its price target to $300. On February 14, 2024, downgrade downgraded it’s rating to Equal Weight and revised its price target to $240 on the stock. UBS downgraded its rating to a Neutral and decreased its price target to $276 on January 24, 2024. Raymond James upgraded its rating to Outperform for this stock on December 07, 2023, but kept the price target unchanged to $283. In a note dated September 06, 2023, HSBC Securities initiated an Buy rating and provided a target price of $360 on this stock.
The stock price of Biogen Inc [BIIB] has been fluctuating between $181.31 and $269.43 over the past year. Currently, Wall Street analysts expect the stock to reach $284.1 within the next 12 months. Biogen Inc [NASDAQ: BIIB] shares were valued at $191.56 at the most recent close of the market. An investor can expect a potential return of 48.31% based on the average BIIB price forecast.
Analyzing the BIIB fundamentals
The Biogen Inc [NASDAQ:BIIB] reported sales of 9.29B for trailing twelve months, representing a surge of 0.09%. Gross Profit Margin for this corporation currently stands at 0.72% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at 0.14%, and Net Profit Margin reading is 0.12%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.08 and Total Capital is 0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 188.13 points at the first support level, and at 184.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 193.48, and for the 2nd resistance point, it is at 195.39.
Ratios To Look Out For
It’s worth pointing out that Biogen Inc [NASDAQ:BIIB]’s Current Ratio is 2.29. As well, the Quick Ratio is 1.48, while the Cash Ratio is 0.61. Considering the valuation of this stock, the price to sales ratio is 3.00, the price to book ratio is 1.76 and price to earnings (TTM) ratio is 24.13.
Transactions by insiders
Recent insider trading involved Singhal Priya, Head of Development, that happened on Sep 03 ’24 when 431.0 shares were sold. Officer, Singhal Priya completed a deal on Sep 03 ’24 to buy 431.0 shares. Meanwhile, Head of Development Singhal Priya sold 93.0 shares on Apr 02 ’24.
